CD40LG and COVID-19: The comprehensive analysis published by the Cochrane COVID-19 Diagnostic Test Accuracy Group has emphasized that anti-SARS-CoV-2 IgG antibodies develop in as many as 90% of all subjects recovering from an acute infection, while anti-SARS-CoV-2 IgM antibodies develop with a substantially lower frequency (i.e., around 70%) [4].